2-(furan-2-yl)butanoic acid | 14497-26-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 2-(furan-2-yl)butanoic acid
• 英文别名: 2-furan-2-yl-butyric acid；2-[2]furyl-butyric acid；2-[2]Furyl-buttersaeure；α-(2-Furyl)-buttersaeure
• CAS: 14497-26-8
• 化学式: C₈H₁₀O₃
• 分子量: 154.166
• InChiKey: OICUGXPFKXWCAS-UHFFFAOYSA-N

物化性质

• 熔点：
  50-50.5 °C
• 沸点：
  82-84 °C(Press: 12 Torr)
• 密度：
  1.0109 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  50.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  ethyl-[2]furyl-malonic acid dimethyl ester 在 sodium hydroxide 作用下， 生成 2-(furan-2-yl)butanoic acid
  参考文献：
  名称：

  呋喃基丙二酸及其某些衍生物

  摘要：

  DOI：

  10.1002/hlca.193401701138

文献信息

• Highly Enantioselective Direct Alkylation of Arylacetic Acids with Chiral Lithium Amides as Traceless Auxiliaries
  作者：Craig E. Stivala、Armen Zakarian

  DOI：10.1021/ja205107x

  日期：2011.8.10

  A direct, highly enantioselective alkylation of arylacetic acids via enediolates using a readily available chiral lithium amide as a stereodirecting reagent has been developed. This approach circumvents the traditional attachment and removal of chiral auxiliaries used currently for this type of transformation. The protocol is operationally simple, and the chiral reagent is readily recoverable.

  已经开发出使用容易获得的手性氨基锂作为立体定向试剂通过烯二醇对芳基乙酸进行直接、高度对映选择性的烷基化。这种方法绕过了目前用于此类转化的手性助剂的传统附着和去除。该方案操作简单，手性试剂易于回收。
• Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
  申请人：Mitokinin, LLC

  公开号：US10167286B2

  公开（公告）日：2019-01-01

  The disclosure is directed to compounds and pharmaceutically acceptable salts thereof for the treatment and/or prevention of neurodegenerative and/or mitochondrial diseases, such as Parkinson's disease and Leigh's disease. The compounds and pharmaceutically acceptable salts thereof are of the class of nitrogenous bases, for example, pyrimidines, purines, pteridines and pharmaceutically acceptable salts thereof.

  本公开涉及用于治疗和/或预防神经退行性疾病和/或线粒体疾病（如帕金森病和利氏病）的化合物及其药学上可接受的盐。这些化合物及其药学上可接受的盐属于含氮碱类，例如嘧啶、嘌呤、蝶啶及其药学上可接受的盐。
• Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
  申请人：The Regents of the University of California

  公开号：US10723737B2

  公开（公告）日：2020-07-28

  Disclosed herein inter alia are compositions and methods useful in the treatment neurodegenerative diseases and cardiomyopathy, and for modulating the activity of PINK1.

  本文特别披露了用于治疗神经退行性疾病和心肌病以及调节 PINK1 活性的组合物和方法。
• COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE
  申请人：Mitokinin, LLC

  公开号：US20170190704A1

  公开（公告）日：2017-07-06

  The present disclosure is directed, in part, to compounds, or pharmaceutically acceptable salts thereof, for the treatment and/or prevention of neurodegenerative disease and/or mitchonodrial disease including Parkinson's disease and Leigh's disease.
• COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY
  申请人：The Regents of the University of California

  公开号：US20180072731A1

  公开（公告）日：2018-03-15

  Disclosed herein inter alia are compositions and methods useful in the treatment neurodegenerative diseases and cardiomyopathy, and for modulating the activity of PINK1.